510(k) device
SPECTRALIS HRA+OCT and variants
Heidelberg Engineering GmbH · Tomography, Optical Coherence (OBO, Class II) · First FDA decision Oct 1, 2010, newest May 7, 2026GlaucomaMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
510(k) pathway
Device trials
4
Naming "SPECTRALIS HRA+OCT"
MAUDE reports
0
Brand "SPECTRALIS HRA+OCT", since 2015
PubMed studies
173
Mentioning "SPECTRALIS HRA+OCT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SPECTRALIS HRA+OCT and variants
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
K253837 · Decided May 7, 2026 · 157 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
K250868 · Decided May 12, 2025 · 49 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
K240221 · Decided Jul 1, 2024 · 157 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SPECTRALIS HRA+OCT", any status and sponsor, newest update first.
IRCCS San RaffaeleAcademic, hospital or other
NCT07720765 · 1,050 participants (planned) · Start Oct 9, 2023 · Primary completion Apr 1, 2030
Device: Optical Coherence Tomography (OCT) - Heidelberg SPECTRALIS HRA+OCT · For: Multiple Sclerosis; Alzheimer Disease; Parkinson Disease and 2 more
Sites: Milan, Italy
Heidelberg Engineering GmbHNot on our public-company list
NCT04661124 · 88 participants · Start Dec 10, 2020 · Primary completion Sep 17, 2021
Device: SPECTRALIS; SPECTRALIS with Flex Module · For: Retinal Disease; Healthy Eyes
Sites: Durham, North Carolina
Wills EyeAcademic, hospital or other
NCT02622191 · 33 participants · Start Nov 2012 · Primary completion Feb 2013
Device: Spectral domain Optical Coherence Tomography · For: Glaucoma
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SPECTRALIS HRA+OCT", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OBO
13 reports: 4 malfunction, 9 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SPECTRALIS HRA+OCT"[tiab]. The summary above synthesizes these.
- Reduced Aqueous Humor Outflow Pathway Arborization in Childhood Glaucoma Eyes.
Gupta S, Zhang X, Panigrahi A, et al. · Transl Vis Sci Technol · 2024Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Deep-Learning-Based Analysis of Disease-Specific Structural Biomarkers on Retinal Sensitivity in Neovascular Age-Related Macular Degeneration.
Reiter GS, Birner K, Schrittwieser J, et al. · Invest Ophthalmol Vis Sci · 2025Research Support, Non-U.S. Gov't
- Correlation between spherical equivalent and biometry parameters in adult Cynomolgus macaque.
Chen K, Wu J, Zhao F, et al. · Exp Eye Res · 2023Research Support, Non-U.S. Gov't
- Inner Retinal Thickness and Vasculature in Patients with Reticular Pseudodrusen.
Kalaw FGP, Alex V, Walker E, et al. · Ophthalmic Res · 2023
- Delayed dark adaptation in central serous chorioretinopathy.
Nigalye A, Pundlik S, Kim J, et al. · Am J Ophthalmol Case Rep · 2021Case Reports
- Fluorescein Aqueous Angiography in Live Normal Human Eyes.
Huang AS, Penteado RC, Saha SK, et al. · J Glaucoma · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Quantitative Fundus Autofluorescence in Non-Neovascular Age-Related Macular Degeneration.
Orellana-Rios J, Yokoyama S, Agee JM, et al. · Ophthalmic Surg Lasers Imaging Retina · 2018Multicenter Study, Research Support, Non-U.S. Gov't
- Comparison of retinal parameters between rhesus and cynomolgus macaques.
He C, Peng J, Jin J, et al. · Exp Anim · 2024
- The Retinal Phenotype Associated with the p.Pro101Thr BEST1 Variant.
Bianco L, Arrigo A, Antropoli A, et al. · Ophthalmol Retina · 2024
- High-Resolution Optical Coherence Tomography in Healthy Individuals Provides Resolution at the Cellular and Subcellular Levels.
Reche J, Stocker AB, Henchoz V, et al. · Transl Vis Sci Technol · 2023Observational Study
- Aqueous Angiographic Outflow Improvement after Trabecular Microbypass in Glaucoma Patients.
Huang AS, Penteado RC, Papoyan V, et al. · Ophthalmol Glaucoma · 2019Comparative Study, Research Support, N.I.H., Extramural
- Lack of Correlation Between Segmental Trabecular Meshwork Pigmentation and Angiographically Determined Outflow in Ex Vivo Human Eyes.
Strohmaier CA, Wanderer D, Zhang X, et al. · J Glaucoma · 2024Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Other devices of this type
Also filed under product code OBO.
- CIRRUS HD-OCT Model 6000Carl Zeiss Meditec, Inc. · 510(k) 2024
- AnterionHeidelberg Engineering GmbH · 510(k) 2026
- Spectralis HRA + OCT and variantsHeidelberg Engineering GmbH · 510(k) 2018
- 3D OPTICAL COHERENCE TOMOGRAPHY 3D OCT-1 (type: Maestro2)Topcon Corporation · 510(k) 2024
- Tomey Cornea/Anterior Segment OCT (CASIA2)Tomey Corporation · 510(k) 2025
- P200TE (A10700)Optos Plc. · 510(k) 2024
- RESCAN 700, CALLISTO eyeCarl Zeiss Meditec, AG · 510(k) 2019
- iVueOptovue, Inc. · 510(k) 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.